stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) EPS (diluted)
Halozyme Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was $2.56, down 25.4% from $3.43 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.93. Over the past ten years it has ranged from −$0.81 (fiscal 2016) to $3.43 (fiscal 2024); the current reading is higher than 82% of that period. Halozyme Therapeutics, Inc. ranks 16th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.56 | (25.36%) |
| FY2024 | $3.43 | 63.33% |
| FY2023 | $2.10 | 45.83% |
| FY2022 | $1.44 | (47.45%) |
| FY2021 | $2.74 | 201.10% |
| FY2020 | $0.91 | — |
| FY2019 | −$0.50 | — |
| FY2018 | −$0.56 | — |
| FY2017 | $0.45 | — |
| FY2016 | −$0.81 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.01 | 5.79% |
| Jun 2026 | $1.90 | 55.74% |
| Mar 2026 | $1.22 | — |
| Dec 2025 | −$1.20 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ASND Ascendis Pharma A/S compare | $12.89 |
| HALO Halozyme Therapeutics, Inc. | $3.93 |
| EXEL Exelixis, Inc. compare | $3.34 |
| JAZZ Jazz Pharmaceuticals PLC compare | $2.95 |
| TECH Bio-Techne Corp compare | $1.15 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| KYMR Kymera Therapeutics, Inc. compare | −$3.62 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on HALO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement